All In Biotech

NDA 220073 · Bristol

Eliquis

Apixaban · Oral · Factor Xa Inhibitor

Priority review

Last checked: Nov 19, 2026Latest source record: Jun 24, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Apr 17, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

283

83 Phase 3, 63 recruiting

FAERS reports

280,966

210,870 serious, 40,921 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS (B) SPINAL/EPIDURAL HEMATOMA (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy, consider coverage with another anticoagulant [see Dosage and Administration (2.5) , Warnings and Precautions (5.1) , and Clinical Studies (14.1) ] . (B) SPINAL/EPIDURAL HEMATOMA Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients for spinal procedures....

What it is approved for

From the label in effect Aug 17, 2026.

ELIQUIS is a factor Xa inhibitor indicated: • to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. (1.1) • for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. (1.2) • for the treatment of DVT and PE, and for the reduction in the risk of recurrent DVT and PE in adult patients following initial therapy. (1.3 , 1.4 , 1.5) • Treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth and older after at least 5 days of initial anticoagulant treatment. (1.6) 1.1 Reduction of Risk of Stroke and Systemic Embolism in Nonvalvular Atrial Fibrillation ELIQUIS is indicated to reduce the risk of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation. 1.2 Prophylaxis of Deep Vein Thrombosis Following Hip or Knee Replacement Surgery ELIQUIS is indicated for the prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE), in adult patients who have undergone hip or knee replacement surgery. 1.3 Treatment of Deep Vein Thrombosis ELIQUIS is indicated for the treatment of adults with deep vein thrombosis (DVT). 1.4 Treatment of Pulmonary Embolism ELIQUIS is indicated for the treatment of adults with pulmonary embolism (PE). 1.5 Reduction in the Risk of Recurrence of Deep Vein Thrombosis and Pulmonary Embolism ELIQUIS is indicated to reduce the risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE) in adult patients following initial therapy. 1.6 Treatment of Venous Thromboembolism and Reduction in the Risk of Recurrent Venous Thromboembolism in Pediatric Patients ELIQUIS is indicated for the...

Mechanism: Apixaban is a selective inhibitor of FXa. It does not require antithrombin III for antithrombotic activity. Apixaban inhibits free and clot-bound FXa, and prothrombinase activity. Apixaban has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, apixaban decreases thrombin generation and thrombus development.

Therapeutic areas: Cardiovascular and metabolic

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Apr 17, 2025 Original approval · Type 3 - New Dosage Form · priority review LabelLetterReview
4 products under this application
  • ELIQUIS · APIXABAN 0.15MG · SUSPENSION, ORAL · Prescription
  • ELIQUIS · APIXABAN 5MG · TABLET, ORAL · Prescription
  • ELIQUIS · APIXABAN 0.5MG · TABLET, ORAL · Prescription
  • ELIQUIS SPRINKLE · APIXABAN 0.15MG · FOR SUSPENSION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Apixaban" as an intervention, any sponsor and status, largest first.

All 283 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • death25,095
  • dyspnoea13,002
  • fatigue12,518
  • off label use12,368
  • atrial fibrillation10,940
  • diarrhoea10,264
  • fall9,795
  • cerebrovascular accident9,076
  • dizziness9,007
  • nausea8,776
  • headache7,976
  • thrombosis7,555

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20051
20072
20087
200920
201036
2011117
201226
20131,174
20143,800
20157,567
201612,344
201717,213
201821,671
201927,146
202030,826
202134,744
202229,838
202326,565
202426,750
202523,878
202617,241

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Eliquis (Apixaban)

2024 spending

$20.8B

Beneficiaries

4,424,796

24,061,332 claims

Per beneficiary

$4,695

$9.64 per unit

View as table
YearSpending
2020$9,936,069,814
2021$12,575,145,852
2022$15,219,812,294
2023$18,273,451,967
2024$20,774,929,225

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 863 on PubMed

Sponsor: Bristol Myers Squibb · Also marketed as Eliquis Sprinkle

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.